整理 | GLP1减重宝典内容团队 如果只看过去两年，中国减重药市场几乎是被硬生生挤出来的。先是诺和诺德的Wegovy在2024年6月获批，并于同年11月在中国正式上 市；随后礼来的替尔泊肽以Mounjaro名义进入中国市场；到2025年7月，信达生物的玛仕度肽上市；到了2026年3月，先维盈，也就是埃 诺格鲁肽，也拿到中国长期体重管理适应症批文。换句话说，中国减重药市场已经不再是外资双雄单挑，而是快速变成外资、本土创新 药和后续跟进者同时挤进场的多方混战。 以前大家总说中国GLP-1管线多，但很多还停留在PPT、临床一期或二期阶段；现在不一样了，已经有多款产品真正拿到批文、真正开 始卖、真正开始拼价格、拼渠道、拼支付、拼患者教育。市场从讲故事阶段，进入了近身肉搏阶段。 ▍已上市的药越来越多，但位置其实并不一样 表面看，今天中国已上市的减重药都归在GLP-1大类里，但它们并不是同一代产品。 第一梯队当然还是诺和诺德和礼来。Wegovy代表的是经典GLP-1路径，替尔泊肽则是GLP-1/GIP双靶点路线，两者都已经在全球市场证 明了放量能力，也都率先在中国教育了减重药市场。Wegovy中国上市时，诺和诺德就明确 ...

The U.S. stock market faced a volatile session on Friday, March 13th, 2026, as investors grappled with a complex mix of escalating geopolitical tensions in the Middle East, surging energy prices, and a wave of disappointing corporate guidance. Following a brutal Thursday session that saw the major averages hit their lowest levels of the year, Friday’s trading began with a modest attempt at a relief rally before selling pressure resumed in the afternoon.Major Market Indexes PerformanceAs of the mid-afternoon ...

Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.The company said internal testing detected a previously unidentified impurity formed when the two substances interact.The drugmaker evaluated compounded products marketed in the U.S. that combine tirzepatide with vitamin B12—also referred to as methylcobalamin, hydroxocobalamin, or cyanocobalamin.Laboratory testing revealed significant levels ...

Key Takeaways Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5B in 2025, about 56% of total company revenues.Medicare's BALANCE Model will allow Zepbound and Mounjaro coverage under Part D plans starting in 2027.LLY plans a potential 2Q26 U.S. launch of oral GLP-1 drug orforglipron, if approved, to expand obesity access.Eli Lilly (LLY) , a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepb ...

Market Overview - Major averages are experiencing declines, with the Dow dropping over 400 points as traders assess fluctuating oil prices and a significant inflation report [1] - Markets are trading cautiously due to volatile energy prices and ongoing geopolitical tensions in the Middle East [1] Oil Market Dynamics - Oil prices surged above $100 and briefly approached $120 earlier in the week due to fears of shipping disruptions through the Strait of Hormuz, but have since retreated to below $90 following a coordinated release of emergency reserves [2] - The International Energy Agency has agreed to release approximately 400 million barrels from global strategic stockpiles to stabilize energy markets after a supply shock driven by conflict [2] Geopolitical Tensions - U.S. forces have sunk several Iranian ships, including 16 minelayers, near the Strait of Hormuz, while reports of incidents involving bulk carriers have emerged, highlighting the fragility of global energy supply routes [3] - These developments have contributed to unstable risk sentiment in the market [3] Inflation Data - Recent inflation data indicates that consumer prices rose by 0.3% month-over-month and 2.4% year-over-year, both figures aligning with consensus expectations [4] Company News - Nike (NKE) has been upgraded to Overweight at Barclays due to operational progress [7] - JPMorgan upgraded Oracle (ORCL), citing improved risk/reward following a selloff [7] - Optimum Communications (OPTU) has been downgraded to Market Perform at Raymond James [7] - Yext (YEXT) has been downgraded to Neutral at Roth Capital [7] - Wells Fargo has assigned an Underweight rating to Harley-Davidson (HOG), citing excessive risk [7] - MasterCard (MA) has launched a new Crypto Partner Program, collaborating with over 85 companies in the digital asset and payments sectors [7] - Eli Lilly (LLY) plans to invest $3 billion in China over the next decade [7] - Playboy (PLBY) has appointed Phillip Picardi as chief brand officer and editor in chief [7] - Shell (SHEL) has declared force majeure on liquefied natural gas contracts with some clients in Asia due to the ongoing Qatar LNG shutdown [7] - AMD (AMD) CEO Lisa Su is set to meet with Samsung (SSNLF) Chairman Jay Lee to discuss cooperation on securing supplies of high-bandwidth memory for AI chipsets [7]

Eli Lilly & Co. warned that the active ingredient in its weight-loss blockbuster Zepbound could pose a risk to patients when mixed with vitamin B12, a combination sold by US drug compounders.Lilly tested compounded products and found “significant levels of an impurity” resulting from a chemical reaction between the vitamin and the active ingredient, tirzepatide, it said Thursday. “People receiving tirzepatide-B12 products from compounders, telehealth companies, medspas, or anyone else should be aware that t ...

为什么要在中国如此大手笔投产，答案其实并不复杂。中国已经成为全球减重药竞争最激烈、也最具潜力的市场之一。一方面，肥胖和 代谢类疾病患者基数庞大；另一方面，随着本土药企集体涌入，未来价格竞争和供应效率竞争都会越来越激烈。在这种背景下，谁能更 快建立本土生产和供应体系，谁就更有机会把先发优势转化为市场份额。礼来这次明确提出，要建立口服固体制剂的本土化生产与供应 体系，并采取内部扩建加外部合作的双轮模式，说明它已经不满足于把中国当作销售市场，而是要把这里直接纳入全球制造网络的重要 一环。 整理 | GLP1减重宝典内容团队 全球减重药大战，正在从临床数据竞争，走向产能、供应链和落地速度的全面比拼。3月11日，礼来宣布，未来十年将在中国累计投资 30亿美元，全面扩展本土供应链产能，重点之一就是为其口服小分子GLP-1受体激动剂orforglipron铺设生产能力。这不是一次普通的 扩产决定，而更像是礼来在中国减重药市场打下的一枚重注。公开信息显示，礼来还将与康龙化成展开战略合作，首期预计投入2亿美 元，用于支持后者相关技术能力建设。消息落地后，康龙化成A股和H股双双走强，市场显然迅速捕捉到了这次合作背后的含金量。 这 ...

整理 | GLP1减重宝典内容团队 3月12日，礼来发布公开警告称，公司检测发现，美国市场上一些将替尔泊肽与维生素B12混合配制的复方产品中，出现了由两者化学反 应产生的显著杂质。这一表态迅速引发市场关注，因为它触及的并不只是复方药合不合规的问题，而是更敏感的患者安全问题。 礼来此次警告的核心，并不是反对维生素B12本身，而是强调替尔泊肽与维生素B12在混合后会生成新的杂质，而这种杂质目前几乎没有 清晰的人体数据。礼来称，现阶段并不知道这些杂质在人体内的短期或长期影响，也不清楚它是否会改变替尔泊肽与GLP-1受体、GIP受 体的相互作用，是否会引发新的毒性或免疫反应，以及它在体内的吸收、分布、代谢和排泄路径会不会因此发生变化。换句话说，真正 令人警惕的，不是已经确认出现了什么严重后果，而是风险边界目前仍然不明。 点击关注，追踪最新GLP-1资讯 这也是为什么礼来的措辞如此强硬。对一家原研药企来说，药物一旦离开标准化生产体系，进入各种复方配制、拼装组合和添加未经验 证成分的路径，药物本身就不再是原来的那个药。尤其是替尔泊肽这类结构复杂、商业价值极高、使用人群又在快速扩张的分子，一旦 被大量用于所谓个体化定制产品 ...

Core Insights - Eli Lilly is positioned to benefit from multiple catalysts, particularly in the weight loss sector and the broader trend towards healthier lifestyles [1] - The upcoming launch of Orforglipron, changes in GLP-1 Medicare/Medicaid eligibility, and the introduction of LillyDirect are expected to enhance the company's market presence [1] Group 1: Company Developments - Eli Lilly is set to launch Orforglipron, which is anticipated to contribute significantly to its growth [1] - The company is also focusing on expanding Medicare/Medicaid eligibility for GLP-1 medications, which could increase access and sales [1] - LillyDirect is another initiative aimed at broadening the company's reach in the market [1] Group 2: Market Trends - There is a growing market theme around weight loss and healthier lifestyles, which Eli Lilly is actively engaging with [1] - The company's strategies align with the increasing consumer demand for health-oriented products and solutions [1]

Eli Lilly warned that the active ingredient in Zepbound could pose a risk to patients when mixed with vitamin B12 https://t.co/2LecIXDQuu ...